Persistence of vaccine-induced measles antibody beyond age 12 months: A comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 1, 2011, Pages

  Fowlkes, Ashley ^a   Witte, Desiree ^b   Beeler, Judy ^c   Audet, Susette ^c   Garcia, Philip ^a   Curns, Aaron ^a   Yang, Chunfu ^a   Fudzulani, Richard ^b   Broadhead, Robin ^b   Bellini, William J ^a   Cutts, Felicity ^d   Helfand, Rita F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF MALAWI   (Malawi)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MEASLES ANTIBODY; MEASLES VACCINE; VIRUS ANTIBODY;

ARTICLE; BLOOD SAMPLING; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALAWI; MALE; MEASLES; MEASLES VACCINATION; OUTCOME ASSESSMENT; PLAQUE REDUCTION NEUTRALIZATION ASSAY; PRIORITY JOURNAL; SEROPREVALENCE; SEX DIFFERENCE; SINGLE DRUG DOSE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MEASLES VIRUS; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS;

ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOENZYME TECHNIQUES; INFANT; MALAWI; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; NEUTRALIZATION TESTS;

EID: 79960857798     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir135     Document Type: Article

References (32)

1. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010. Published Online May 12, 2010; DOI:10.1016/S0140-6736(10) 60549-1. http://www.childinfo. org/mortality-overview.html.
2. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 35:349-60.
3. World Health Organization. Measles surveillance data. http://www.who.int/immunization-monitoring/diseases/measles-monthlydata/en/ index.html. Accessed 18 March 2010.
4. Fine PEM. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15:265-302.
5. World Health Organization. Immunization surveillance, assessment and monitoring: african region profile. http://apps.who.int/immunization-monitoring/ en/globalsummary/GS-AFRProfile.pdf. Accessed 14 December 2010.
6. Joint United Nations Programme on HIV/AIDS (UNAIDS) and world health organization (WHO) 2009. AIDS epidemic update: November 2009. http://data.unaids.org/pub/Report/2009/JC1700-Epi-Update-2009-en.pdf. Accessed 13 May 2010.
7. Scott S, Cumberland P, Shulman CE, et al. Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis 2005; 191:1854-60.
8. Farquhar C, Nduati R, Haigwood N, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr 2005; 40:494-7.
9. Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis 1992; 165:262-7.
10. Moss WJ, Fisher C, Scott S, et al. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis 2008; 46:523-7.
11. Helfand RF, Witte D, Fowlkes AL, et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008; 198:1457-65.
12. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3:251-60.
13. Ou CY, Yang H, Balinandi S, et al. Identification of HIV-1 infected infants and young children using real-time RT PCR and dried blood spots from Uganda and Cameroon. J Virol Methods 2007; 144:109-14.
14. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
15. Cohen BJ, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007; 26:59-66.
16. World Health Organization. Response to measles outbreaks in measles mortality reduction settings. Immunization, Vaccines and Biologicals. Geneva, Switzerland: World Health Organization, 2009. http://whqlibdoc.who.int/hq/2009/ WHO-IVB-09.03-eng.pdf. Accessed 7 January 2011.
17. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007; 196:347-55.
18. Nair N, Moss WJ, Scott S, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis 2009; 200:1031-8.
19. Arpadi SM, Markowitz LE, Baughman AL, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996; 97:653-7.
20. Al-Attar I, Reisman J, Muehlmann M, McIntosh K. Decline of measles antibody titers after immunization in human immunodeficiency virus- infected children. Pediatr Infect Dis J 1995; 14:149-51.
21. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Persistence of measles mumps and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1415-8.
22. Johnson CE, Nalin DR, Chui LW, et al. Measles vaccine immuno-genicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics 1994; 93:939-44.
23. Carson MM, Spady DW, Beeler JA, et al. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age. Vaccine 2005; 23:3247-55.
24. Wallace MR, Hooper DG, Graves SJ, Malone JL. Measles seroprevalence and vaccine response in HIV-1 infected adults. Vaccine 1994; 12:1222-4.
25. Molton J, Smith C, Chaytor S, et al. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect 2010; 61:73-80.
26. Kemper CA, Gangar M, Arias G, Kane C, Deresinski SC. The prevalence of measles antibody in human immunodeficiency virus-infected patients in northern California. J Infect Dis 1998; 178: 1177-80.
27. Cutts FT, Grabowsky M, Markowitz LE. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 1995; 23:95-106.
28. Markowitz LE, Sepulveda J, Diaz-Ortega JL, et al. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 1990; 322:580-7.
29. Erratum in: N Engl J Med 1990; 322:863.
30. Cutts FT, Nyandu B, Markowitz LE, et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine 1994; 12:1311-6.
31. Biellik R, Madema S, Taole A, et al. First 5 years of measles elimination in southern Africa: 1996-2000. Lancet 2002; 359:1564-8.
32. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants in resource-limited settings: towards universal access: recommendations for a public health approach. Geneva: World Health Organization, 2006. http://www.who.int/reproductivehealth/ publications/rtis/9241594667/en/index.html. Accessed 22 December 2010.